%0 Journal Article
%A Gerhäuser, Clarissa
%A Favero, Francesco
%A Risch, Thomas
%A Simon, Ronald
%A Feuerbach, Lars
%A Assenov, Yassen
%A Heckmann, Doreen
%A Sidiropoulos, Nikos
%A Waszak, Sebastian M
%A Hübschmann, Daniel
%A Urbanucci, Alfonso
%A Girma, Etsehiwot G
%A Kuryshev, Vladimir
%A Klimczak, Leszek J
%A Saini, Natalie
%A Stütz, Adrian M
%A Weichenhan, Dieter
%A Böttcher, Lisa-Marie
%A Toth, Reka
%A Hendriksen, Josephine D
%A Koop, Christina
%A Lutsik, Pavlo
%A Matzk, Sören
%A Warnatz, Hans-Jörg
%A Amstislavskiy, Vyacheslav
%A Feuerstein, Clarissa
%A Raeder, Benjamin
%A Bogatyrova, Olga
%A Schmitz, Eva-Maria
%A Hube-Magg, Claudia
%A Kluth, Martina
%A Huland, Hartwig
%A Graefen, Markus
%A Lawerenz, Christian
%A Henry, Gervaise H
%A Yamaguchi, Takafumi N
%A Malewska, Alicia
%A Meiners, Jan
%A Schilling, Daniela
%A Reisinger, Eva-Maria
%A Eils, Roland
%A Schlesner, Matthias
%A Strand, Douglas W
%A Bristow, Robert G
%A Boutros, Paul C
%A von Kalle, Christof
%A Gordenin, Dmitry
%A Sültmann, Holger
%A Brors, Benedikt
%A Sauter, Guido
%A Plass, Christoph
%A Yaspo, Marie-Laure
%A Korbel, Jan O
%A Schlomm, Thorsten
%A Weischenfeldt, Joachim
%T Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.
%J Cancer cell
%V 34
%N 6
%@ 1535-6108
%C New York, NY
%I Elsevier
%M DKFZ-2018-02264
%P 996 - 1011.e8
%D 2018
%X Identifying the earliest somatic changes in prostate cancer can give important insights into tumor evolution and aids in stratifying high- from low-risk disease. We integrated whole genome, transcriptome and methylome analysis of early-onset prostate cancers (diagnosis ≤55 years). Characterization across 292 prostate cancer genomes revealed age-related genomic alterations and a clock-like enzymatic-driven mutational process contributing to the earliest mutations in prostate cancer patients. Our integrative analysis identified four molecular subgroups, including a particularly aggressive subgroup with recurrent duplications associated with increased expression of ESRP1, which we validate in 12,000 tissue microarray tumors. Finally, we combined the patterns of molecular co-occurrence and risk-based subgroup information to deconvolve the molecular and clinical trajectories of prostate cancer from single patient samples.
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:30537516
%R 10.1016/j.ccell.2018.10.016
%U https://inrepo02.dkfz.de/record/142034